Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04210245 · ClinicalTrials.gov registry record · Phase 2
Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)
A Phase 2 study, sponsored by NGM Biopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT04210245 is a Phase 2 study that has completed, run by NGM Biopharmaceuticals. The registered enrollment target is 160 participants.
The verdict
NCT04210245, a Phase 2 study, has completed, sponsored by NGM Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
A multi-center evaluation of aldafermin in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis.
Interventions
- OTHER Placebo
- BIOLOGICAL aldafermin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2020-03-23 |
| Est. Completion | 2023-02-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04210245
The ClinicalTrials.gov registry entry for NCT04210245 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NGM Biopharmaceuticals, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04210245 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04210245 about?
NCT04210245 is a clinical study titled "Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)". A multi-center evaluation of aldafermin in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis.
What is the current status of trial NCT04210245?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2020-03-23. Estimated completion is 2023-02-23.
What interventions are being tested in trial NCT04210245?
The interventions under investigation include: Placebo (OTHER), aldafermin (BIOLOGICAL).
Who is sponsoring clinical trial NCT04210245?
This trial is sponsored by NGM Biopharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.